TY  - JOUR
AU  - Jimenez, Veronica
AU  - Jambrina, Claudia
AU  - Casana, Estefania
AU  - Sacristan, Victor
AU  - Muñoz, Sergio
AU  - Darriba, Sara
AU  - Rodó, Jordi
AU  - Mallol, Cristina
AU  - Garcia, Miquel
AU  - León, Xavier
AU  - Marcó, Sara
AU  - Ribera, Albert
AU  - Elias, Ivet
AU  - Casellas, Alba
AU  - Grass, Ignasi
AU  - Elias, Gemma
AU  - Ferré, Tura
AU  - Motas, Sandra
AU  - Franckhauser, Sylvie
AU  - Mulero, Francisca
AU  - Navarro, Marc
AU  - Haurigot, Virginia
AU  - Ruberte, Jesus
AU  - Bosch, Fatima
PY  - 2018
DO  - 10.15252/emmm.201708791
SN  - 1757-4676
UR  - http://hdl.handle.net/20.500.12105/6561
AB  - Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (FGF21)...
LA  - eng
KW  - AAV gene therapy
KW  - FGF21
KW  - insulin resistance
KW  - obesity
KW  - type 2 diabetes
TI  - FGF21 gene therapy as treatment for obesity and insulin resistance
TY  - journal article
ER  -